Short answer
Candel Therapeutics, Inc. (CADL) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal Q2 2026 results for quarter ended June 30, 2026.
Candel Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal Q2 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains the financial results
- Disclosure furnished, not filed under Exchange Act Section 18
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 R&D rose to $19.8M from $7.0M, reflecting accelerated prostate-cancer development and manufacturing investment
- Net loss widened to $38.9M from $4.8M, including $12.2M expense from warrant-liability revaluation
- Cash increased to $201.6M, funding current plans into Q1 2028, including potential 2027 commercialization
- Prostate phase 3 showed 39% improvement in cancer-specific disease-free survival after 58 months across 745 patients
- Planned Q4 2026 BLA submission is the key near-term catalyst, with approval still required before commercialization
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Candel Therapeutics, Inc. 8-K filings
Get the next CADL 8-K as it lands
Follow CADL for push alerts, or ask the research agent what this filing means.